Aprea Therapeutics, Inc. (APRE)
Largest Insider Buys in Sector
APRE Stock Price History Chart
APRE Stock Performance
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Insider Activity of Aprea Therapeutics, Inc.
Over the last 12 months, insiders at Aprea Therapeutics, Inc. have bought $121,962 and sold $0 worth of Aprea Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aprea Therapeutics, Inc. have bought $9.82M and sold $31.41M worth of stock each year.
Highest buying activity among insiders over the last 12 months: HENNEMAN JOHN B III (director) — $250,047. Seizinger Bernd R. (director) — $100,019. Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr) — $14,726.
The last purchase of 2,000 shares for transaction amount of $14,580 was made by Gilad Oren (President, CEO) on 2024‑03‑13.
List of Insider Buy and Sell Transactions, Aprea Therapeutics, Inc.
| 2024-03-13 | Gilad Oren | President, CEO | 2,000 0.0683% | $7.29 | $14,580 | -3.60% | ||
| 2024-03-13 | Seizinger Bernd R. | director | 6,860 0.2342% | $7.29 | $50,009 | -3.60% | ||
| 2024-03-13 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 1,010 0.0345% | $7.29 | $7,363 | -3.60% | ||
| 2024-03-13 | HENNEMAN JOHN B III | director | 6,860 0.2342% | $7.29 | $50,009 | -3.60% | ||
| 2023-06-07 | Seizinger Bernd R. | director | 6,029 0.1917% | $3.68 | $22,192 | +21.41% | ||
| 2023-06-06 | Seizinger Bernd R. | director | 4,068 0.1208% | $3.63 | $14,764 | +13.87% | ||
| 2020-12-28 | Sale | Redmile Group, LLC | 10 percent owner | 500,000 2.4014% | $5.58 | $2.79M | -11.73% | |
| 2020-10-05 | Sale | 5AM Ventures IV, L.P. | Former 10% holder | 175,000 0.7844% | $25.30 | $4.43M | -80.91% | |
| 2020-07-07 | Sale | KDev Investments AB | 10 percent owner | 241,703 1.1593% | $34.55 | $8.35M | -79.65% | |
| 2020-06-16 | Sale | ROCKLAGE SCOTT M | Former 10% holder | 120,164 0.5556% | $33.30 | $4M | -38.45% | |
| 2020-06-16 | Sale | 5AM Ventures IV, L.P. | Former 10% holder | 140,000 0.6473% | $33.30 | $4.66M | -38.45% | |
| 2020-06-11 | Sale | ROCKLAGE SCOTT M | Former 10% holder | 245,000 1.1106% | $28.75 | $7.04M | -27.94% | |
| 2020-06-11 | Sale | 5AM Ventures IV, L.P. | Former 10% holder | 245,000 1.1106% | $28.75 | $7.04M | -27.94% | |
| 2020-05-19 | Sale | ROCKLAGE SCOTT M | Former 10% holder | 255,000 1.3734% | $35.15 | $8.96M | -20.89% | |
| 2020-05-19 | Sale | 5AM Ventures IV, L.P. | Former 10% holder | 255,000 1.3734% | $35.15 | $8.96M | -20.89% | |
| 2020-04-13 | Sale | KDev Investments AB | 10 percent owner | 210,548 0.9223% | $31.25 | $6.58M | -22.96% | |
| 2019-10-07 | HealthCap VII, L.P. | 10 percent owner | 266,667 0.9722% | $15.00 | $4M | +53.58% | ||
| 2019-10-07 | Christenson Johan | director | 266,667 0.9722% | $15.00 | $4M | +53.58% | ||
| 2019-10-07 | Redmile Group, LLC | 10 percent owner | 400,000 1.4583% | $15.00 | $6M | +53.58% | ||
| 2019-10-07 | Versant Vantage I, L.P. | 10 percent owner | 333,333 1.2152% | $15.00 | $5M | +53.58% |
Insider Historical Profitability
| Gilad Oren | President, CEO | 324770 8.6914% | $4.02 | 1 | 0 | |
| Seizinger Bernd R. | director | 33685 0.7045% | $4.02 | 3 | 0 | +17.64% |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 15503 0.4149% | $4.02 | 1 | 0 | |
| HENNEMAN JOHN B III | director | 8139 0.1338% | $4.02 | 2 | 0 | +53.58% |
| Christenson Johan | director | 2366104 63.3212% | $4.02 | 1 | 0 | +53.58% |
| HealthCap VII, L.P. | 10 percent owner | 2366104 63.3212% | $4.02 | 1 | 0 | +53.58% |
| KDev Investments AB | 10 percent owner | 1992586 53.3252% | $4.02 | 0 | 2 | |
| Redmile Group, LLC | 10 percent owner | 1768718 47.3341% | $4.02 | 1 | 1 | +53.58% |
| Versant Vantage I, L.P. | 10 percent owner | 333333 8.9206% | $4.02 | 1 | 0 | +53.58% |
| Versant V Luxco S.a r.l. | 10 percent owner | 333333 8.9206% | $4.02 | 1 | 0 | +53.58% |
| 5AM Ventures IV, L.P. | Former 10% holder | 138497 3.7064% | $4.02 | 1 | 4 | +53.58% |
| ROCKLAGE SCOTT M | Former 10% holder | 75965 2.033% | $4.02 | 0 | 3 | |
| Magni Guido | director | 6500 0.174% | $4.02 | 1 | 0 | +53.58% |
| SCHADE CHRISTIAN S | President & CEO | 5000 0.1338% | $4.02 | 1 | 0 | +53.58% |
| Coiante Scott M | SVP, Chief Financial Officer | 2500 0.0669% | $4.02 | 1 | 0 | +53.58% |
| Korbel Gregory Alan | VP of Business Dev't | 500 0.0134% | $4.02 | 1 | 0 | +53.58% |
| Attar Eyal C. | SVP, Chief Medical Officer | 200 0.0054% | $4.02 | 1 | 0 | +53.58% |
Institutional Investor Ownership
No records found… | |||||||